Opportunity and innovation for pharma, biotechs, healthcare and investors
Dr. Howard K. Koh is the Assistant Secretary for Health for the U.S. Department of Health and Human Services. He oversees 14 core public health offices — including the Office of the Surgeon General and the US Public Health Service Corps — as well as 10 regional health o…more ›
Axel van Trotsenburg has been the World Bank’s Vice-President for Concessional Finance and Global Partnerships since August 2009. In this capacity, Mr. van Trotsenburg leads the policy negotiations and replenishment process for the International Development Association …more ›
Dr. Gary Nabel serves as Director of the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health. Dr. Nabel provides overall direction and scientific leadership of the basic, clinical, and translat…more ›
Peter J. Hotez, M.D., Ph.D., is Professor of Pediatrics and Molecular Virology & Microbiology at Baylor College of Medicine where he is also chief of a new Section of Pediatric Tropical Medicine and founding Dean of the National School of Tropical Medicine. In addit…more ›
Paul A. Offit, MD is the Chief of the Division of Infectious Diseases and the Director of the Vaccine Education Center at the Children’s Hospital of Philadelphia. In addition, Dr. Offit is the Maurice R. Hilleman Professor of Vaccinology and a Professor of Pediatrics at…more ›
THE WORLD'S LARGEST VACCINE PARTNERING EVENT
Do you want to meet over 750 senior vaccine professionals to forge new partnerships and discover new commercial opportunities?
For the 12th year running delegates from all parts of the vaccine value chain come to World Vaccine Congress Washington to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior congresses have produced many highly successful business partnerships.
Have a look at the constantly updated list of participants on the right and check out the program and speakers on the left or download the brochure here.
Sponsors
The event at a glance in 2012:
- Domestic and global immunization initiatives
- Vaccine financing schemes and strategies
- Vaccine vision, revolutionary focus and scientific breakthroughs
- Emerging markets - Public health authorities, private opportunities, policy and regulations
- Therapeutic vaccines
- Prophylactic vaccines
- Global market evaluation and target identification strategies
- Novel partnership models
- Project management and commercilaization
- Outsourcing and technology transfer best practice
- Influenza vaccines - novel designs & next generation
- Pricing strategies and policies revisited
Testimonial
“Simply a great conference!
The event continues to deliver what we are looking for”
George Adams | Asia/India Market Manager, Vaccine Program Manager | EMD Millipore
Biotech Speed venturing
Showcase your Early-Stage Biotech in front of 50 of the industry’s leading Venture Capital and Private Equity investors.
Academic poster sessions
NEW Scientific Poster opportunities for exclusive and previously unpublished scientific.
The 5th annual ViE Awards
The Vie nominations are closing on the 15th Feb – have you indicated yet which vaccine candidates addressed current unmet medical need?
NEW CO-LOCATED BRANDS TO 2012
Vaccine trial optimization for sponsors, CROs and clinical trial sites and eClinical providers
Advance your clinical trials effectively and efficiently and overcome the biggest hurdle to placing your vaccine candidate on the market. Learn about:
- An evolving model for vaccine clinical trials and R&D
- Globalisation of the vaccine clinical trial model
- Reducing attrition in the vaccine clinical trial process
- Optimising clinical trial outsourcing partnerships
- Site selection and study conduct prioritisation
- Efficient patient recruitment and retention
- Efficient clinical data collection and management
- Clinical trial endpoints vs. real-world endpoints
- Implementing innovative adaptive clinical design
- eClinical trial technologies and improved efficiency
- Overcoming increasingly stringent regulation
- Collaborative strategies for regulatory approval outcomes
Production and manufacture process optimization for pharma, biotech and contract partners
Adopt production capabilities and establish robust and efficient manufacturing processes for vaccine development and manufacturing advances. Learn about:
- New manufacturing strategy selection and adoption
- Overcoming process development challenges for new vaccines
- Upstream and downstream process integration
- Upstream process collection and harvesting
- Commercial scale clarification, purification and inactivation
- Efficient formulation final fill and finish
- Controlling costs of complex manufacturing processes
- Novel technologies redesigning vaccine phases
- Entrenching disposable / single-use system application
- Enabling efficient outsourced manufacturing activities
- Promoting vaccine production in developing countries
Commercial development opportunities for pharma, biotech, CMOs and media providers
Conf
Apply cell-culture-based processes and technologies as a robust, reliable and practical means to streamline vaccine bioprocess and scale-up. Learn about:
- Cell culture in the age of vaccines
- Cell-line engineering vs. cell culture media
- Cell line engineering and selection strategies
- Media screening and selection methods
- The acceptance and application of fed-batch cultures
- Vaccine upstream process optimisation
- Vaccine process scale-up and downstream integration
- Feeding strategies to meet vaccine production needs
- Downstream process bottlenecks and challenges
- Cell culture cultivation and purification
- Improving cell culture facilities and disposables
